Rankings
▼
Calendar
AXSM Q4 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AXSM
Axsome Therapeutics, Inc.
$9B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$72M
+193.5% YoY
Gross Profit
$64M
89.7% margin
Operating Income
-$98M
-137.4% margin
Net Income
-$99M
-137.9% margin
EPS (Diluted)
$-2.08
QoQ Revenue Growth
+23.8%
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$30M
Stock-Based Comp.
$19M
Balance Sheet
Total Assets
$588M
Total Liabilities
$397M
Stockholders' Equity
$191M
Cash & Equivalents
$386M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$72M
$24M
+193.5%
Gross Profit
$64M
$22M
+190.5%
Operating Income
-$98M
-$60M
-64.0%
Net Income
-$99M
-$61M
-61.1%
Revenue Segments
Product
$71M
99%
Royalty
$783,000
1%
← FY 2023
All Quarters
Q1 2024 →